Literature DB >> 9684652

The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan.

K Hiramatsu1.   

Abstract

Within the past year, infections caused by methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to vancomycin (MIC=8 microg/mL) have been reported in both Japan and the United States. The emergence of these strains poses a potentially serious threat to public health. After 2 such strains (Mu3 and Mu50) were identified at Juntendo Hospital in 1996, a screening program to identify MRSA strains with reduced susceptibility to vancomycin was initiated. Of 970 MRSA strains tested at 195 nonuniversity hospitals throughout Japan, 13 (1.3%) were found to have subpopulations with reduced vancomycin susceptibility (heterogeneous vancomycin resistance). Among 129 MRSA strains identified at 7 university hospitals, 12 (9.3%) demonstrated heterogeneity for vancomycin resistance; 1 of these strains had a vancomycin MIC of 7 microg/mL. Although resistance in these strains is not the result of the transfer of enterococcal vancomycin resistance genes (vanA or vanB), the clonal dissemination of MRSA strains with vancomycin-resistant subpopulations is obviously undesirable. Intensified testing of MRSA strains for resistance to vancomycin and appropriate measures for the prevention of the spread of such strains are recommended.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684652     DOI: 10.1016/s0002-9343(98)00149-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  48 in total

1.  Glycopeptide Resistance in Staphylococcus aureus.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

2.  Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis.

Authors:  M R Mulvey; L Chui; J Ismail; L Louie; C Murphy; N Chang; M Alfa
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  Methicillin-Resistant Staphylococcus aureus Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

Review 4.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 5.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

6.  Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Kim Credito; Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Colonization with vancomycin-intermediate Staphylococcus aureus strains containing the vanA resistance gene in a tertiary-care center in north India.

Authors:  Tuhina Banerjee; Shampa Anupurba
Journal:  J Clin Microbiol       Date:  2012-02-15       Impact factor: 5.948

8.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

9.  Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus.

Authors:  J E Finan; G L Archer; M J Pucci; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.

Authors:  Dianne B Hoellman; Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.